**Adult: Neuro-Oncology Treatment**

**High Grade Glioma**
- IRB# 21095: A Multicenter Phase 2 Study of Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) in Recurrent WHO Grade IV Malignant Glioma Patients.
- IRB# 16046: Response Assessment to Pembrolizumab with Standard of Care Therapy in Glioblastoma Using Ferumoxytol Steady State Imaging – A Pilot Study.

**Low Grade Glioma**
- IRB# 21284: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects with Residual or Recurrent Grad 2 Glioma with an IDH1 or IDH2 Mutation.

**Recurrent**

**Metastatic Non-Small Cell Lung Carcinoma**
- IRB# 16709: The use of perfusion MRI using ferumoxytol and small molecular weight gadolinium agents to assess response to pembrolizumab in brain metastases and systemic lesions in NSCLC: A comparison of imaging modalities to address brain metastases, pseudoprogression and systemic lesion tumor flare.

**Newly Diagnosed**
- IRB# 21263: A Phase 2b Trial of the MEK1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients with Neurofibromatosis Type 1 (NF1) Associated Inoperable Plexiform Neurofibromas (PNs) that are Causing Significant Morbidity.

**Low Grade Glioma**
- IRB# 21263: A Phase 2b Trial of the MEK1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients with Neurofibromatosis Type 1 (NF1) Associated Inoperable Plexiform Neurofibromas (PNs) that are Causing Significant Morbidity.

**High Grade Glioma**
- IRB# 21263: A Phase 2b Trial of the MEK1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients with Neurofibromatosis Type 1 (NF1) Associated Inoperable Plexiform Neurofibromas (PNs) that are Causing Significant Morbidity.

**Key**
- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php